VEGFA and neoplasm: In contrast, in patients with an unfavorable genetic profile, the microenvironment conditions due to the different genotype combinations may result in an increase of the VEGF-A production and/or the presence of an altered VEGFR-2 on tumor endothelial cells which may be capable to proliferate, migrate or survive because the VEGF action is not completely blocked by bevacizumab.